← All trials
NCT01155258
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2010
- Primary completion
- Jan 1, 2013
- Completion date
- May 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 19
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of Southern CaliforniaLead sponsor
- University of Southern CaliforniaOverall official - principal investigator
- WyethCollaborator
Drugs studied
Indications studied
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms
- Glioma
- Intestinal Neoplasms
- Leiomyosarcoma
- Neoplasm Metastasis
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Pheochromocytoma
- Sarcoma
- Thyroid Neoplasms
- Endometrial Neoplasms
- Carcinoma, Islet Cell
- Neuroendocrine Tumors
- Breast Neoplasms, Male
- Small Cell Lung Carcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.